These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26131063)

  • 21. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis.
    Tantai XX; Yang LB; Wei ZC; Xiao CL; Chen LR; Wang JH; Liu N
    World J Gastroenterol; 2019 Jun; 25(21):2683-2698. PubMed ID: 31210719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
    Lau YT; Ahmed NN
    Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
    Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
    J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
    Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G
    Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies.
    Cheungpasitporn W; Thongprayoon C; Kittanamongkolchai W; Srivali N; Edmonds PJ; Ungprasert P; O'Corragain OA; Korpaisarn S; Erickson SB
    Ren Fail; 2015 Aug; 37(7):1237-41. PubMed ID: 26108134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis.
    Byun JH; Jang S; Lee S; Park S; Yoon HK; Yoon BH; Ha YC
    J Bone Metab; 2017 Feb; 24(1):37-49. PubMed ID: 28326300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis.
    Nassar Y; Richter S
    J Bone Metab; 2018 Aug; 25(3):141-151. PubMed ID: 30237993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the Use of Proton Pump Inhibitors Increase the Risk of Pancreatic Cancer? A Systematic Review and Meta-Analysis of Epidemiologic Studies.
    Hong HE; Kim AS; Kim MR; Ko HJ; Jung MK
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32784492
    [No Abstract]   [Full Text] [Related]  

  • 31. The relationship among proton pump inhibitors, bone disease and fracture.
    Targownik LE; Leslie WD
    Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
    Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
    Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.
    Kwok CS; Arthur AK; Anibueze CI; Singh S; Cavallazzi R; Loke YK
    Am J Gastroenterol; 2012 Jul; 107(7):1011-9. PubMed ID: 22525304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis.
    Hafiz RA; Wong C; Paynter S; David M; Peeters G
    Ann Pharmacother; 2018 Jul; 52(7):613-622. PubMed ID: 29457492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term proton pump inhibitor therapy and risk of hip fracture.
    Yang YX; Lewis JD; Epstein S; Metz DC
    JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
    Song H; Zhu J; Lu D
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants.
    Green DS; Abdel-Latif ME; Jones LJ; Lui K; Osborn DA
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD011785. PubMed ID: 31265739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved.
    Thong BKS; Ima-Nirwana S; Chin KY
    Int J Environ Res Public Health; 2019 May; 16(9):. PubMed ID: 31060319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
    Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
    Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.